Michael Brave

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer
    Michael Brave
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Oncology (Williston Park) 20:1401-4, 1410; discussion 1410-11, 1415-6. 2006
  2. ncbi Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
    Michael Brave
    Office of Oncology Drug Products, Office of New Drugs, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
    Clin Cancer Res 14:352-9. 2008
  3. ncbi FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation
    Michael Brave
    Office of Oncology Drug Products, Office of New Drugs, Michael Brave U S Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA
    Oncology 78:282-8. 2010

Detail Information

Publications3

  1. ncbi Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer
    Michael Brave
    Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, USA
    Oncology (Williston Park) 20:1401-4, 1410; discussion 1410-11, 1415-6. 2006
    ..The purpose of this summary is to review the database supporting this approval...
  2. ncbi Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate
    Michael Brave
    Office of Oncology Drug Products, Office of New Drugs, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA
    Clin Cancer Res 14:352-9. 2008
    ..This summary reviews the database supporting this approval...
  3. ncbi FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation
    Michael Brave
    Office of Oncology Drug Products, Office of New Drugs, Michael Brave U S Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA
    Oncology 78:282-8. 2010
    ..This summary reviews the database supporting this approval...